Bladder Cancer, Carcinoma, Colorectal Cancer, Melanoma
Conditions
Keywords
Melanoma, Bladder Cancer, Colorectal Cancer, tumor neo-antigen DC vaccine, safety, clinical efficacy
Brief summary
This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal cancer. Then, we intended to explore the safety and efficacy of individual tumor antigen-sensitized DC vaccine and their sensitized T cells in these solid cancers.
Interventions
BIOLOGICALTumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
subcutaneous administration
Sponsors
Sichuan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age:18-75 years * Pathologically diagnosed advanced (stage IV) malignant melanoma, bladder cancer or colorectal cancer with measurable lesions; * Failed in the previous standard therapy; * ECOG PS (Eastern Cooperative Oncology Group performance status) score 0-2 points; * The estimated survival period is ≥3 months; * Rehabilitate from previous therapy; * Adequate organ functions; * Patient's written informed consent;
Exclusion criteria
* Tumor emergencies; * Abnormal coagulation function; * Contagious diseases, such as HIV, HBV, HCV infection; * Mental disorders; * Concomitant tumors; * Immunological co-morbidities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0 | 3 months after the last administration of cells | Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with Overall survival as assessed by RECIST1.1 | through study completion, an average of 1 year |
Countries
China
Contacts
Primary ContactJi-Yan Liu, Prof
Outcome results
None listed